Cypriots — who hold the rotating presidency of the Council of the European Union until the end of June — tested the waters on what countries aim to achieve through the Commission’s proposed Biotech Act — and, unsurprisingly, an additional year of monopoly rights for certain treatments divided countries.
In the meantime, EU health chief, Várhelyi, said this is the way to have access to new therapies.